Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial

Journal name:
Nature Medicine
Volume:
17,
Pages:
366–371
Year published:
DOI:
doi:10.1038/nm.2316
Received
Accepted
Published online

Abstract

We analyzed HIV-1 genome sequences from 68 newly infected volunteers in the STEP HIV-1 vaccine trial. To determine whether the vaccine exerted selective T cell pressure on breakthrough viruses, we identified potential T cell epitopes in the founder sequences and compared them to epitopes in the vaccine. We found greater distances to the vaccine sequence for sequences from vaccine recipients than from placebo recipients. The most significant signature site distinguishing vaccine from placebo recipients was Gag amino acid 84, a site encompassed by several epitopes contained in the vaccine and restricted by human leukocyte antigen (HLA) alleles common in the study cohort. Moreover, the extended divergence was confined to the vaccine components of the virus (HIV-1 Gag, Pol and Nef) and not found in other HIV-1 proteins. These results represent what is to our knowledge the first evidence of selective pressure from vaccine-induced T cell responses on HIV-1 infection in humans.

At a glance

Figures

  1. Maximum-likelihood phylogenetic tree of gag sequences.
    Figure 1: Maximum-likelihood phylogenetic tree of gag sequences.

    The tree comprises nucleotide sequences from each individual along with the MRKAd5, HXB2 and CON_B04 sequences and is rooted with sequences from the only subject not infected with a subtype B virus (CRF02-AG). Sequences from placebo recipients are in blue, whereas sequences from vaccine recipients are in red. Sequences from individuals with two or more founder variants are highlighted in yellow. The sequences from related viruses found in two individuals are labeled with the two subjects' identification numbers. The scale bar at the bottom refers to the degree of the sequence mismatch.

  2. Epitope-specific protein distances between epitopes from founder sequences and the MRKAd5 HIV-1 vaccine sequence.
    Figure 2: Epitope-specific protein distances between epitopes from founder sequences and the MRKAd5 HIV-1 vaccine sequence.

    (ad) Comparison of epitopic distances across treatment assignment based on NetMHC predictions using Gag, Pol and Nef epitopes combined (a), or separately (b–d), respectively. Mean distance values are indicated.

  3. Protein distances between epitopes from founder sequences and HXB2 or HIV-1 CON_B04.
    Figure 3: Protein distances between epitopes from founder sequences and HXB2 or HIV-1 CON_B04.

    (ad) Epitopic distances based on NetMHC predictions are compared across treatment groups, separately for epitopes derived from Gag, Pol and Nef (vaccine insert) (a,c) and for epitopes derived from the six other HIV-1 proteins (b,d). a and b are compared to HXB2; c and d are compared to CON_B04. Mean distance values are indicated.

  4. Amino acid signature sites.
    Figure 4: Amino acid signature sites.

    Ten amino acid signature sites distinguishing vaccine and placebo recipients are represented with bar graphs. Each bar represents the amino acid found in one individual: the upper, black bars represent the individuals with an amino acid matching the MRKAd5 HIV-1 insert at that position and the lower, red bars correspond to individuals with a mismatched amino acid.

  5. Summary of sequence analyses and IFN-[gamma] ELISPOT data.
    Figure 5: Summary of sequence analyses and IFN-γ ELISPOT data.

    (af) Data from Gag (a,b), Nef (c,d) and Pol (e,f). For each protein, the top graph (a,c,e) represents the location of predicted epitopes based on NetMHC in vaccine and placebo groups (light and medium gray columns, respectively), amino acid signature sites (dashed lines) and signature k-mers (horizontal bars). The bottom graph (b,d,f) corresponds to IFN-γ ELISPOT responses detected in 21 vaccine recipients before infection. Fifteen–amino-acid peptides overlapping by 11 amino acids were used to assess responses. The region covered by each responsive peptide is shown as the box width, whereas the number of subjects reacting with that peptide is given by the box height.

Accession codes

Referenced accessions

GenBank/EMBL/DDBJ

References

  1. Buchbinder, S.P. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the STEP Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 18811893 (2008).
  2. McElrath, M.J. et al. HIV-1 vaccine–induced immunity in the test-of-concept STEP Study: a case-cohort analysis. Lancet 372, 18941905 (2008).
  3. Leitner, T. et al. HIV Sequence Compendium 2005 648 and viii (Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, 2006).
  4. Buus, S. et al. Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. Tissue Antigens 62, 378384 (2003).
  5. Brumme, Z.L. et al. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS ONE 4, e6687 (2009).
  6. Frahm, N. et al. Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur. J. Immunol. 37, 24192433 (2007).
  7. Korber, B.T.M. et al. HIV Molecular Immunology (Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, New Mexico, 2006/2007).
  8. Betts, M.R. et al. Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc. Natl. Acad. Sci. USA 102, 45124517 (2005).
  9. Kelleher, A.D. et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27–restricted cytotoxic T lymphocyte responses. J. Exp. Med. 193, 375386 (2001).
  10. Feeney, M.E. et al. Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27–positive long-term-nonprogressing child. J. Virol. 78, 89278930 (2004).
  11. Goulder, P.J. et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3, 212217 (1997).
  12. Reece, J.C. et al. Timing of immune escape linked to success or failure of vaccination. PLoS ONE 5, e12774 (2010).
  13. Rolland, M., Nickle, D.C. & Mullins, J.I. HIV-1 Group M conserved elements vaccine. PLoS Pathog. 3, e157 (2007).
  14. Yewdell, J.W. Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 25, 533543 (2006).
  15. Lafuente, E.M. & Reche, P.A. Prediction of MHC-peptide binding: a systematic and comprehensive overview. Curr. Pharm. Des. 15, 32093220 (2009).
  16. Heckerman, D., Kadie, C. & Listgarten, J. Leveraging information across HLA alleles/supertypes improves epitope prediction. J. Comput. Biol. 14, 736746 (2007).
  17. Nickle, D.C. et al. HIV-specific probabilistic models of protein evolution. PLoS ONE 2, e503 (2007).
  18. Gilbert, P.B., Wu, C. & Jobes, D.V. Genome scanning tests for comparing amino acid sequences between groups. Biometrics 64, 198207 (2008).
  19. Tarone, R.E. A modified Bonferroni method for discrete data. Biometrics 46, 515522 (1990).

Download references

Author information

  1. These authors contributed equally to this work.

    • Morgane Rolland,
    • Sodsai Tovanabutra,
    • Allan C deCamp &
    • Nicole Frahm

Affiliations

  1. Department of Microbiology, University of Washington, Seattle, Washington, USA.

    • Morgane Rolland,
    • Laura Heath,
    • Kim Wong,
    • Hong Zhao,
    • Dana N Raugi,
    • Stephanie Sorensen,
    • Julia N Stoddard,
    • Brandon S Maust,
    • Wenjie Deng &
    • James I Mullins
  2. US Military HIV Research Program, Rockville, Maryland, USA.

    • Sodsai Tovanabutra,
    • Eric Sanders-Buell,
    • Meera Bose,
    • Andrea Bradfield,
    • Annemarie O'Sullivan,
    • Jacqueline Crossler,
    • Teresa Jones,
    • Marty Nau,
    • Nelson L Michael,
    • Jerome Kim &
    • Francine E McCutchan
  3. Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

    • Allan C deCamp,
    • Nicole Frahm,
    • Peter B Gilbert,
    • Craig A Magaret,
    • John Hural,
    • Lawrence Corey,
    • Fusheng Li,
    • Steve G Self,
    • Ann Duerr &
    • M Juliana McElrath
  4. Merck Research Laboratories, West Point, Pennsylvania, USA.

    • Sheri Dubey,
    • John Shiver,
    • Danilo R Casimiro &
    • Michael N Robertson
  5. San Francisco Department of Health, San Francisco, California, USA.

    • Susan Buchbinder
  6. Present address: Bill and Melinda Gates Foundation, Seattle, Washington, USA.

    • Francine E McCutchan

Contributions

M.R., A.C.D., P.B.G., and J.I.M. designed the sequence analysis. M.R., A.C.D., P.B.G., C.A.M., L.H., B.S.M., W.D., F.L. and J.I.M. conducted the analyses. M.R., A.C.D., N.F., P.B.G. and J.I.M. analyzed the data. M.R., A.C.D., N.F., P.B.G. and J.I.M. wrote the manuscript. J.I.M., F.E.M., S.T., E.S.-B. and N.F. designed lab experiments. M.B., A.B., A.O., J.C., T.J., M.N., K.W., H.Z., D.N.R., S.S., J.N.S. and N.F. performed lab experiments. J.H., L.C., S.B., D.R.C., M.N.R., A.D., M.J.M., S.G.S., S.D., N.L.M., J.K. and J.S. conducted the STEP trial, provided material and oversaw laboratories.

Competing financial interests

M.N.R. and D.R.C. are paid employees of Merck, own Merck stock and have Merck stock options.

Corresponding author

Correspondence to:

Author details

Supplementary information

PDF files

  1. Supplementary Text and Figures (2M)

    Supplementary Methods, Supplementary Results, Supplementary Tables 1 and 2 and Supplementary Figures 1–5

Additional data